Quantcast

Latest Boehringer Ingelheim Stories

2014-08-20 23:05:37

Top Healthcare Talent, Companies and Brand Champions to be Honored September 18th New York, NY (PRWEB) August 20, 2014 The finalists are in for the sixth-annual PM360 Trailblazer Awards. PM360, a leading health-marketing industry trade magazine, will honor the pharmaceutical industry’s most influential innovators. Established in 2009, the Trailblazer Awards are given to outstanding companies, marketers and brand managers representing the best the industry has to offer. “We are proud...

2014-08-18 20:21:55

INDIANAPOLIS and RIDGEFIELD, Conn., Aug. 18, 2014 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) today granted tentative approval for Basaglar(TM) (insulin glargine injection), which is indicated to improve glycemic control in adults with type 2 diabetes and in combination with mealtime insulin in adults and pediatric patients with type 1 diabetes. Basaglar is not recommended for the treatment of diabetic ketoacidosis. Basaglar is Eli Lilly and Company (NYSE: LLY) and...

2014-08-17 23:00:12

All Aspects Of Litigation Surrounding The Federal Pradaxa Lawsuits Alleging Boehringer Ingelheim's Blood Thinner Caused Serious Internal Bleeding Have Been Suspended Until Completion Of A Settlement Agreement Reports Wright & Schulte LLC Columbus, OH (PRWEB) August 18, 2014 The attorneys at Wright & Schulte LLC note all matters within the Pradaxa lawsuit litigation were recently placed on hold while plaintiffs’ attorneys and Pradaxa manufacturer Boehringer Ingelheim...

2014-08-14 16:27:26

Committee Voted Based on Clinical Data from Eight Efficacy Trials RIDGEFIELD, Conn., Aug. 14, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) Pulmonary-Allergy Drugs Advisory Committee (PADAC) voted [10 yes, 3 no] that existing data supports approval of Boehringer Ingelheim's investigational tiotropium bromide inhalation spray for long-term, once-daily maintenance treatment of bronchospasm associated...

2014-08-13 23:11:30

Thousands of Pradaxa Lawsuits Currently Pending in U.S. Courts Accuse Boehringer Ingelheim of Failing to Provide Adequate Warnings Regarding Medication’s Alleged Bleeding Side Effects New York NY (PRWEB) August 13, 2014 Pradaxa Lawsuit News: As Pradaxa lawsuits continue to move forward in U.S. courts, several new reports published in the British Medical Journal are raising new questions about the data used to garner regulatory approval of the blood thinner. Among other things, the...

2014-08-11 23:00:19

Donna Ames is recognized as an NAPW VIP Woman of the Year for her outstanding leadership and commitment within her profession Garden City, NY (PRWEB) August 12, 2014 NAPW honors Donna Ames as a 2014 Professional Woman of the Year for coordinating clinical trials with this prestigious distinction. As the largest, most-recognized networking organization of women in the country, spanning virtually every industry and profession, the National Association of Professional Women (NAPW) is a...

2014-08-11 12:27:45

AstraZeneca, Boehringer Ingelheim, Eli Lilly & Company, Ferring Pharmaceuticals, Inc., Forest Laboratories, Inc., GlaxoSmithKline, Novartis, Novo Nordisk, Pearl Therapeutics, Pfizer, Sanofi, Chiltern International, ICON plc, INC Research, inVentiv Health, Parexel International, Pharmaceutical Research Associates (PRA), Quintiles, and Target Health Inc. ELLICOTT CITY, Md., Aug. 11, 2014 /PRNewswire/ -- The Society for Clinical Research Sites (SCRS), the trade organization representing...

2014-08-02 00:21:08

Third product from the BI-Lilly Diabetes alliance to be approved by FDA RIDGEFIELD, Conn., and INDIANAPOLIS, Aug. 1, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and Eli Lilly and Company (NYSE: LLY) today announced the U.S. Food and Drug Administration (FDA) approved Jardiance® (empagliflozin) tablets as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes (T2D). JARDIANCE is not for people with type 1...

2014-07-31 12:29:00

DUBLIN, July 31, 2014 /PRNewswire/ -- Research and Markets has announced the addition of the "Global Parkinson's Disease Market 2014-2018" report to their offering. http://photos.prnewswire.com/prnh/20130307/600769 Parkinson's disease is a progressive neurodegenerative disorder characterized by damage of dopaminergic neurons located in various parts of brain including the substantia nigra. This lowers the concentration of dopamine in the striatum. A decrease in dopamine levels by 80 percent...

2014-07-23 16:26:55

British Medical Journal publishes biased article regarding PRADAXA RIDGEFIELD, Conn., July 23, 2014 /PRNewswire/ -- Boehringer Ingelheim (BI) wants to set the record straight following misleading statements that the British Medical Journal (BMJ) published today regarding Pradaxa® (dabigatran etexilate mesylate). We are concerned that this publication may alarm patients and prompt them to stop taking PRADAXA, thereby increasing their risk of stroke. To be clear, many of the allegations made...


Word of the Day
mallemaroking
  • Nautical, the visiting and carousing of sailors in the Greenland ships.
This word is apparently from a confusion of two similar Dutch words: 'mallemerok,' a foolish woman, and 'mallemok,' a name for some persons among the crew of a whaling vessel.